.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,992,982

« Back to Dashboard

Claims for Patent: 8,992,982

Title:Formulation of indomethacin
Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
Inventor(s): Dodd; Aaron (Centennial Park, AU), Meiser; Felix (Claremont, AU), Norret; Marck (Darlington, AU), Russell; Adrian (Rivervale, AU), Bosch; H. William (Bryn Mawr, PA)
Assignee: Iceutica Pty Ltd. (Balcatta WA, AU)
Application Number:14/282,915
Patent Claims: 1. A solid unit dose of a pharmaceutical composition containing 20 mg of indomethacin wherein the unit dose when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37.degree. C. in 900 ml of 100 mM citric acid buffer (pH 5.5.+-.0.05) has a dissolution rate of indomethacin such that at least 83%, by weight, is released by 75 minutes and wherein the D90 of the indomethacin, on a particle volume basis, is selected from the group consisting of: less than 5000 nm, less than 4000 nm, 3000 nm, less than 2000 nm, less than 1900 nm, less than 1800 nm, and less than 1700 nm.

2. The solid unit dose of a pharmaceutical composition of claim 1, wherein the unit dose has a dissolution rate of indomethacin such that at least 83%, by weight, is released by 60 minutes.

3. The solid unit dose of a pharmaceutical composition of claim 1, wherein the unit dose has a dissolution rate of indomethacin such that at least 83%, by weight, is released by 45 minutes.

4. The solid unit dose of a pharmaceutical composition of claim 1, wherein the unit dose has a dissolution rate of indomethacin such that at least 83%, by weight, is released by 30 minutes.

5. The solid unit dose of a pharmaceutical composition of claim 1, wherein the unit dose has a dissolution rate of indomethacin such that at least 83%, by weight, is released by 20 minutes.

6. The solid unit dose of a pharmaceutical composition of claim 1, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 1000 nm.

7. The solid unit dose of a pharmaceutical of claim 1 wherein the indomethacin has a median particle size, on a particle volume basis, between 25 nm and 700 nm.

8. A solid unit dose of a pharmaceutical composition containing 40 mg of indomethacin wherein the unit dose when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37.degree. C. in 900 ml of 100 mM citric acid buffer (pH 5.5.+-.0.05) has a dissolution rate of indomethacin such that at least 66%, by weight, is released by 75 minutes and wherein the D90 of the indomethacin, on a particle volume basis, is selected from the group consisting of: less than 5000 nm, less than 4000 nm, 3000 nm, less than 2000 nm, less than 1900 nm, less than 1800 nm, and less than 1700 nm.

9. The solid unit dose of a pharmaceutical composition of claim 8, wherein the unit dose has a dissolution rate of indomethacin such that at least 66%, by weight, is released by 60 minutes.

10. The solid unit dose of a pharmaceutical composition of claim 8, wherein the unit dose has a dissolution rate of indomethacin such that at least 66%, by weight, is released by 45 minutes.

11. The solid unit dose of a pharmaceutical composition of claim 8, wherein the unit dose has a dissolution rate of indomethacin such that at least 66%, by weight, is released by 30 minutes.

12. The solid unit dose of a pharmaceutical composition of claim 8, wherein the unit dose has a dissolution rate of indomethacin such that at least 66%, by weight, is released by 20 minutes.

13. The solid unit dose of a pharmaceutical composition of claim 8, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 1000 nm.

14. The solid unit dose of a pharmaceutical composition of claim 8, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 700 nm.

15. The solid unit dose of claim 1 wherein the unit dose is a tablet.

16. The solid unit dose of claim 8 wherein the unit dose is a tablet.

17. The solid unit dose of claim 5 wherein the D90 of the indomethacin, on a particle volume, basis is less than 5000 nm.

18. The solid unit dose of claim 12 wherein the D90 of the indomethacin, on a particle volume, basis is less than 5000 nm.

19. The solid unit dose of a pharmaceutical composition of claim 1, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 700 nm.

20. The solid unit dose of a pharmaceutical composition of claim 8, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 700 nm.

21. The solid unit dose of claim 1 wherein the D90 of the indomethacin, on a particle volume, basis is less than 3000 nm.

22. The solid unit dose of claim 8 wherein the D90 of the indomethacin, on a particle volume, basis is less than 3000 nm.

23. The solid unit dose of a pharmaceutical composition of claim 4, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 600 nm.

24. The solid unit dose of a pharmaceutical composition of claim 11, wherein the indomethacin has a median particle size, on a volume average basis, between 25 nm and 600 nm.

25. The solid unit dose of a pharmaceutical composition of claim 1, wherein the unit dose has a dissolution rate of indomethacin such that at least 99%, by weight, is released by 30 minutes.

26. The solid unit dose of a pharmaceutical composition of claim 8, wherein the unit dose has a dissolution rate of indomethacin such that at least 93%, by weight, is released by 30 minutes.

27. The solid unit dose of a pharmaceutical composition of claim 25, wherein the D90 of the indomethacin, on a particle volume, basis is less than 5000 nm.

28. The solid unit dose of a pharmaceutical composition of claim 26, wherein the D90 of the indomethacin, on a particle volume, basis is less than 5000 nm.

29. The solid unit dose of a pharmaceutical composition of claim 1, wherein a single dose provides perceptible pain relief to a patient suffering from acute pain.

30. The solid unit dose of a pharmaceutical composition of claim 8, wherein a single dose provides perceptible pain relief to a patient suffering from acute pain.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc